Trace Metal Limits in (R)-Azepan-3-amine for Ophthalmic Use
ICP-MS Trace Metal Specifications for (R)-Azepan-3-amine in Ophthalmic Grade Purity
When formulating sterile ophthalmic suspensions, the presence of trace transition metals in the chiral amine building block (3R)-azepan-3-amine can directly impact product stability and patient safety. As a key intermediate in besifloxacin synthesis, the (R)-azepan-3-amine must meet stringent elemental impurity limits per ICH Q3D guidelines. Our industrial purity grade is controlled via ICP-MS to ensure iron (Fe) ≤ 5 ppm, copper (Cu) ≤ 2 ppm, and total heavy metals ≤ 10 ppm. These limits are critical because even sub-ppm levels of redox-active metals can catalyze oxidative degradation of the fluoroquinolone core in the final formulation.
In our hands-on field experience, a non-standard parameter that often surprises formulators is the viscosity shift of (R)-azepan-3-amine at sub-zero temperatures. While the compound remains liquid at room temperature, storage at -20°C can lead to a noticeable increase in viscosity, which may affect handling during cold-chain operations. This behavior is not typically captured in standard COAs but is crucial for planning bulk transfers in cold environments. For exact batch-specific data, please refer to the batch-specific COA.
Our (R)-Azepan-3-amine with verified trace metal profile serves as a drop-in replacement for other commercial sources, offering identical technical parameters while ensuring supply chain reliability. The azepan-3-amine r-isomer is manufactured under strict quality control, with every batch accompanied by a comprehensive COA detailing the impurity profile, including residual solvents and chiral purity.
| Parameter | Standard Grade | Ophthalmic Grade |
|---|---|---|
| Assay (GC) | ≥ 98.0% | ≥ 99.0% |
| Chiral Purity (ee) | ≥ 99.0% | ≥ 99.5% |
| Iron (Fe) | ≤ 10 ppm | ≤ 5 ppm |
| Copper (Cu) | ≤ 5 ppm | ≤ 2 ppm |
| Total Heavy Metals | ≤ 20 ppm | ≤ 10 ppm |
| Water (KF) | ≤ 0.5% | ≤ 0.2% |
For a deeper understanding of how our impurity profile compares to other suppliers, see our detailed analysis on drop-in replacement for Enamine ENA514234333: (R)-Azepan-3-amine COA & impurity profile.
Mechanistic Pathways of Copper and Iron-Catalyzed Oxidative Degradation in Fluoroquinolone Suspensions
Copper and iron ions are well-known catalysts for Fenton-type reactions, generating reactive oxygen species (ROS) that can attack the fluoroquinolone nucleus. In besifloxacin ophthalmic suspensions, even trace amounts of these metals can lead to the formation of N-oxide impurities and color bodies, compromising both efficacy and appearance. The 3-aminoazepane moiety, being a secondary amine, can also participate in metal-catalyzed oxidation, potentially forming nitrosamine impurities under certain conditions. Therefore, controlling metal content at the intermediate stage is far more effective than attempting to remove them downstream.
Our manufacturing process for (R)-azepan-3-amine employs metal-free reduction conditions and rigorous purification steps to minimize metal carryover. This is particularly important when the intermediate is used in a besifloxacin precursor role, as any metal contamination can poison the palladium catalysts used in subsequent coupling reactions. We have observed that iron levels above 10 ppm can significantly reduce catalyst turnover, leading to incomplete conversions and increased impurity formation. This field insight is crucial for process chemists scaling up the synthesis route.
To further explore how moisture and isomer control impact catalyst performance, read our article on resolving catalyst poisoning in besifloxacin synthesis: (R)-Azepan-3-amine moisture & isomer control.
Chelating Agent Compatibility and Formulation Strategies to Mitigate Metal-Induced Color Shift
In ophthalmic suspensions, chelating agents like EDTA or DTPA are commonly added to sequester trace metals and prevent oxidative degradation. However, the azepane ring in (R)-azepan-3-amine can interact with certain chelators, potentially affecting the pH and tonicity of the formulation. Our technical support team has investigated the compatibility of our low-metal (R)-azepan-3-amine with common ophthalmic excipients. We found that at typical use levels (0.01-0.05% w/v EDTA), there is no adverse interaction, and the chiral integrity of the amine is maintained over the shelf life.
A practical edge case we've encountered is the crystallization of (R)-azepan-3-amine in the presence of certain buffer salts at low temperatures. While the free base is a liquid, its hydrochloride salt can crystallize if the formulation pH drops below 4.5. This is a non-standard parameter that formulators should consider when designing the suspension vehicle. Our COA includes a note on the recommended storage conditions to avoid such phase changes.
Bulk Packaging and Stability Considerations for Low-Metal (R)-Azepan-3-amine Intermediates
For global manufacturers, the logistics of shipping (R)-azepan-3-amine require careful attention to packaging to maintain the low-metal specification. We supply the product in 210L HDPE drums or 1000L IBC totes, both with nitrogen blanketing to prevent oxidative degradation during transit. The material is classified as a corrosive liquid (UN 2735) and must be handled accordingly. Our packaging is designed to minimize extractables and leachables that could reintroduce metal contamination.
Stability studies under accelerated conditions (40°C/75% RH) have shown that our ophthalmic grade (R)-azepan-3-amine maintains its purity and metal limits for at least 12 months when stored in the original sealed containers. We recommend retesting after 24 months for extended storage. The bulk price is competitive, and we offer flexible supply agreements to meet your production schedules.
Frequently Asked Questions
What are the acceptable heavy metal ppm limits for (R)-azepan-3-amine in ophthalmic applications?
For ophthalmic use, we recommend iron ≤ 5 ppm, copper ≤ 2 ppm, and total heavy metals ≤ 10 ppm as per ICH Q3D guidelines for parenteral products. These limits ensure minimal risk of metal-catalyzed degradation in the final formulation.
What is the difference between ICP-MS and AAS testing for trace metals in this intermediate?
ICP-MS offers superior sensitivity and multi-element detection capabilities compared to AAS. For (R)-azepan-3-amine, ICP-MS can quantify metals at sub-ppm levels with higher accuracy, which is essential for meeting ophthalmic grade specifications. AAS may be suitable for routine iron testing but lacks the breadth of analysis needed for a full elemental impurity profile.
How do metal chelators like EDTA interact with the azepane ring?
At typical formulation concentrations, EDTA does not chemically react with the azepane ring. However, it can affect the protonation state of the amine, potentially altering solubility. Our studies show no degradation or racemization of (R)-azepan-3-amine in the presence of EDTA under normal storage conditions.
Can (R)-azepan-3-amine be used as a drop-in replacement for other suppliers' material?
Yes, our product is designed as a seamless drop-in replacement, matching the technical parameters of leading commercial sources. We provide detailed COAs and offer sample batches for qualification to ensure compatibility with your existing synthesis route.
Sourcing and Technical Support
As a dedicated global manufacturer of (R)-azepan-3-amine, NINGBO INNO PHARMCHEM CO.,LTD. provides consistent quality, competitive bulk pricing, and comprehensive technical support. Our team of experts can assist with impurity profiling, method transfer, and regulatory documentation. Partner with a verified manufacturer. Connect with our procurement specialists to lock in your supply agreements.